Saturday 17 October 2026
Export CELU’s income statement to Excel — free account
Celularity, Inc.
CELU Healthcare Biotechnology
Celularity, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $26.6 million, down 51.0% from fiscal 2024. In the quarter to March 2026, revenue fell 66.3%, EPS grew 103.6%, free cash flow grew 148.4% and total debt fell 4.73%, each against the same quarter a year earlier.
1.25
0.08
−6.02%
Follow CELU
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 1 | 1 | 1 |
| (6,372.77%) | 5,736.39% | 628.23% | 349.83% | ||
| (57.65%) | (66.41%) | (76.50%) | (62.45%) | ||
ROIC |
(172.59%) | (153.64%) | (1,070.92%) | (695.71%) | |
Return on Tangible Assets |
(1,099.18%) | (3,220.71%) | 726.09% | 734.06% | |
Average Days of Receivables |
91.29 | 60.31 | 63.97 | 91.99 | |
Free Cash Flow per Share |
(0.11) | (0.25) | (0.52) | (0.30) | |
Free Cash Flow |
(2.54) | (6.56) | (13.25) | (8.81) | |
| Other line items | |||||
Cash ROIC |
(13.52%) | (32.81%) | (83.21%) | (141.89%) | |
Accounts Receivable Turnover |
3.62 | 5.24 | 2.92 | 1.92 | |
Accounts Payable Turnover |
1.05 | 1.00 | 0.81 | 0.74 | |
Inventory Turnover |
5.47 | 6.14 | 6.71 | 5.39 | |
Average Days of Payables |
444.81 | 447.75 | 480.42 | 509.77 | |
Days of Inventory on Hand |
80.39 | 46.67 | 10.38 | 9.69 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
33.24% | 38.21% | 56.59% | 75.33% | |
Selling, General and Administrative Expense of Revenue |
124.70% | 128.79% | 193.09% | 243.38% | |
Share Based Compensation of Revenue |
23.99% | 24.81% | 39.09% | 47.36% | |
Interest Coverage |
(5.94) | (6.33) | (9.08) | (13.06) | |
Operating CF/Net income |
0.03 | 0.08 | 0.14 | 0.12 | |
Depreciation/Fixed assets |
0.13 | 0.13 | 0.13 | 0.13 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
1.86 | 1.54 | 1.04 | 0.65 | |
Operating CF per Share |
(0.11) | (0.25) | (0.52) | (0.30) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 1 Oct 2026